These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30375911)

  • 1. Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study.
    Lund CM; Vistisen KK; Dehlendorff C; Rønholt F; Johansen JS; Nielsen DL
    Acta Oncol; 2018 Nov; 57(11):1445-1454. PubMed ID: 30375911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
    Gouverneur A; Coutureau J; Jové J; Rouyer M; Grelaud A; Duc S; Gérard S; Smith D; Ravaud A; Droz C; Bernard MA; Lassalle R; Forrier-Réglat A; Noize P;
    Clin Colorectal Cancer; 2019 Mar; 18(1):e150-e162. PubMed ID: 30630730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS).
    Decoster L; Kenis C; Naessens B; Houbier G; De Man M; Lambrecht G; Monsaert E; Moons V; Vergauwe P; Prenen H; Van Cutsem E; Wildiers H
    J Geriatr Oncol; 2018 Mar; 9(2):93-101. PubMed ID: 29133190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
    Kabbinavar FF; Hurwitz HI; Yi J; Sarkar S; Rosen O
    J Clin Oncol; 2009 Jan; 27(2):199-205. PubMed ID: 19064978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer.
    Reynolds J; Chamberland-Tremblay A; Herrington JD; Munoz Maldonado Y; Wong L
    J Oncol Pharm Pract; 2017 Apr; 23(3):173-178. PubMed ID: 26786027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
    Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
    Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
    Landre T; Maillard E; Taleb C; Ghebriou D; Guetz GD; Zelek L; Aparicio T
    Int J Colorectal Dis; 2018 Aug; 33(8):1125-1130. PubMed ID: 29680896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
    Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
    Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
    Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
    Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
    Betge J; Barat A; Murphy V; Hielscher T; Van Grieken NC; Belle S; Zhan T; Härtel N; Kripp M; Bacon O; Cordes M; Kay EW; Verheul HM; Neerincx M; Hennessy B; Hofheinz RD; Gaiser T; Ylstra B; Prehn JH; Lambrechts D; Byrne AT; Ebert MP; Schulte N
    Digestion; 2016; 94(3):129-137. PubMed ID: 27756074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
    Vijayvergia N; Li T; Wong YN; Hall MJ; Cohen SJ; Dotan E
    Cancer; 2016 Oct; 122(20):3191-3198. PubMed ID: 27379436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.